Two Sigma Advisers’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-11,900
| Closed | -$904K | – | 1634 |
|
|
2025
Q4 | $904K | Sell |
11,900
-3,300
| -22% | -$240K | ﹤0.01% | 1528 |
|
|
2025
Q3 | $933K | Sell |
15,200
-44,542
| -75% | -$2.32M | ﹤0.01% | 1494 |
|
|
2025
Q2 | $2.92M | Sell |
59,742
-129,700
| -68% | -$6.16M | 0.01% | 958 |
|
|
2025
Q1 | $9.65M | Sell |
189,442
-171,000
| -47% | -$8.53M | 0.02% | 540 |
|
|
2024
Q4 | $16.3M | Sell |
360,442
-69,400
| -16% | -$2.97M | 0.04% | 374 |
|
|
2024
Q3 | $15.9M | Buy |
429,842
+40,300
| +10% | +$1.35M | 0.04% | 367 |
|
|
2024
Q2 | $11.9M | Sell |
389,542
-3,700
| -0.9% | -$120K | 0.03% | 489 |
|
|
2024
Q1 | $11.4M | Buy |
393,242
+203,400
| +107% | +$5.7M | 0.03% | 494 |
|
|
2023
Q4 | $5.23M | Sell |
189,842
-14,300
| -7% | -$327K | 0.01% | 787 |
|
|
2023
Q3 | $4.57M | Sell |
204,142
-82,300
| -29% | -$3.06M | 0.01% | 784 |
|
|
2023
Q2 | $11.6M | Sell |
286,442
-42,200
| -13% | -$2.06M | 0.03% | 445 |
|
|
2023
Q1 | $15.9M | Buy |
328,642
+9,700
| +3% | +$443K | 0.04% | 396 |
|
|
2022
Q4 | $12.2M | Buy |
318,942
+45,900
| +17% | +$1.91M | 0.03% | 460 |
|
|
2022
Q3 | $13.7M | Buy |
+273,042
| New | +$13.4M | 0.04% | 413 |
|
|
2022
Q1 | – | Sell |
-5,500
| Closed | -$219K | – | 2872 |
|
|
2021
Q4 | $219K | Buy |
+5,500
| New | +$211K | ﹤0.01% | 2256 |
|
|
2021
Q1 | – | Sell |
-7,000
| Closed | -$427K | – | 2687 |
|
|
2020
Q4 | $427K | Sell |
7,000
-41,400
| -86% | -$2.44M | ﹤0.01% | 1923 |
|
|
2020
Q3 | $2.26M | Sell |
48,400
-213,842
| -82% | -$10.5M | 0.01% | 1095 |
|
|
2020
Q2 | $13.3M | Sell |
262,242
-43,900
| -14% | -$2.16M | 0.04% | 450 |
|
|
2020
Q1 | $13.7M | Buy |
306,142
+41,400
| +16% | +$2.08M | 0.05% | 385 |
|
|
2019
Q4 | $12.7M | Buy |
+264,742
| New | +$11.2M | 0.03% | 515 |
|
|
2019
Q3 | – | Sell |
-7,500
| Closed | -$338K | – | 2360 |
|
|
2019
Q2 | $338K | Sell |
7,500
-48,300
| -87% | -$1.91M | ﹤0.01% | 1967 |
|
|
2019
Q1 | $2.1M | Sell |
55,800
-11,300
| -17% | -$379K | 0.01% | 1199 |
|
|
2018
Q4 | $2.3M | Sell |
67,100
-100,600
| -60% | -$3.62M | 0.01% | 1116 |
|
|
2018
Q3 | $7.88M | Sell |
167,700
-222,500
| -57% | -$9.21M | 0.02% | 655 |
|
|
2018
Q2 | $13.2M | Buy |
390,200
+50,600
| +15% | +$1.58M | 0.04% | 503 |
|
|
2018
Q1 | $9.19M | Buy |
+339,600
| New | +$8.6M | 0.02% | 614 |
|
|
2016
Q3 | – | Sell |
-161,100
| Closed | -$1.13M | – | 2289 |
|
|
2016
Q2 | $1.13M | Sell |
161,100
-64,700
| -29% | -$475K | 0.01% | 1106 |
|
|
2016
Q1 | $1.45M | Buy |
+225,800
| New | +$3.92M | 0.01% | 946 |
|
|
2015
Q3 | – | Sell |
-6,400
| Closed | -$308K | – | 1943 |
|
|
2015
Q2 | $308K | Sell |
6,400
-7,800
| -55% | -$455K | ﹤0.01% | 1604 |
|
|
2015
Q1 | $864K | Buy |
14,200
+9,200
| +184% | +$561K | 0.01% | 1138 |
|
|
2014
Q4 | $259K | Buy |
+5,000
| New | +$220K | ﹤0.01% | 2041 |
|
Other funds holding PTCT
RI
AC
Two Sigma Advisers's PTCT Position: Q1 2026 in Review
Two Sigma Advisers sold out of PTC Therapeutics (PTCT) in Q1 2026, closing a stake of 11,900 shares — an estimated $904K sold.
Two Sigma Advisers first reported a position in PTCT in Q4 2014 and held it in 31 quarters. The position peaked at $16.3M in Q4 2024. 352 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.
- Two Sigma Advisers reported no remaining PTC Therapeutics position as of Q1 2026 after selling out during the quarter.
- Two Sigma Advisers sold 11,900 PTC Therapeutics shares in Q1 2026, an estimated $904K.
- Two Sigma Advisers first reported a position in PTC Therapeutics in Q4 2014 and held it in 31 quarters.
- Two Sigma Advisers's PTC Therapeutics position peaked at $16.3M in Q4 2024.
- 352 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.
Based on Two Sigma Advisers's 13F filing for Q1 2026.